Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults with Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl

American Journal of Cardiology

Volumn 116, Issue 11, 2015, Pages 1700-1704

  Rana, Jamal S ^a,b,c   Liu, Jennifer Y ^c   Moffet, Howard H ^c   Solomon, Matthew D ^a,d   Go, Alan S ^c,d   Jaffe, Marc G ^a   Karter, Andrew J ^c  

^a KAISER PERMANENTE   (United States)

^b DIVISION OF RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHILD; DIABETES MELLITUS; DYSLIPIDEMIA; ETHNICITY; FEMALE; FOLLOW UP; HEALTH CARE; HUMAN; HYPERTENSION; ICD-9; INSTITUTIONAL REVIEW; INTEGRATED HEALTH CARE SYSTEM; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPTOMETRY; PRIORITY JOURNAL; SCHOOL CHILD; SMOKING; BLOOD; CORONARY DISEASE; DIABETIC ANGIOPATHY; DYSLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; RISK ASSESSMENT;

ADULT; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; RISK ASSESSMENT;

EID: 84947313617     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2015.08.039     Document Type: Article

References (16)

1. B.G. Brown, K.H. Stukovsky, and X.Q. Zhao Simultaneous low-density lipoprotein-C lowering and high-density lipoprotein-C elevation for optimum cardiovascular disease prevention with various drug classes, and their combinations: a meta-analysis of 23 randomized lipid trials Curr Opin Lipidol 17 2006 631 636
2. N. Sarwar, J. Danesh, G. Eiriksdottir, G. Sigurdsson, N. Wareham, S. Bingham, S.M. Boekholdt, K.T. Khaw, and V. Gudnason Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies Circulation 115 2007 450 458
3. J.S. Rana, M.E. Visser, B.J. Arsenault, J.P. Després, E.S. Stroes, J.J. Kastelein, N.J. Wareham, S.M. Boekholdt, and K.T. Khaw Metabolic dyslipidemia and risk of future coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study Int J Cardiol 143 2010 399 404
4. ACCORD Study Group H.N. Ginsberg, M.B. Elam, L.C. Lovato, J.R. Crouse 3rd, L.A. Leiter, P. Linz, W.T. Friedewald, J.B. Buse, H.C. Gerstein, J. Probstfield, R.H. Grimm, F. Ismail-Beigi, J.T. Bigger, D.C. Goff Jr., W.C. Cushman, D.G. Simons-Morton, and R.P. Byington Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 2010 1563 1574
5. J.R. Guyton, A.E. Slee, T. Anderson, J.L. Fleg, R.B. Goldberg, M.L. Kashyap, S.M. Marcovina, S.D. Nash, K.D. O'Brien, W.S. Weintraub, P. Xu, X.Q. Zhao, and W.E. Boden Relationship of lipoproteins to cardiovascular events: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1580 1584
6. N. Krieger Overcoming the absence of socioeconomic data in medical records validation and application of a census-based methodology Am J Public Health 82 1992 703 710
7. R.W. Yeh, S. Sidney, M. Chandra, M. Sorel, J.V. Selby, and A.S. Go Population trends in the incidence and outcomes of acute myocardial infarction N Engl J Med 362 2010 10 2155 2165
8. A.J. Karter, D. Schillinger, A.S. Adams, H.H. Moffet, J. Liu, N.E. Adler, and A.M. Kanaya Elevated rates of diabetes in Pacific Islanders and Asian subgroups: the diabetes study of Northern California (DISTANCE) Diabetes Care 36 2013 574 579
9. Prospective Diabetes UK. Study 27. Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex Diabetes Care 20 1997 1683 1687
10. W.B. Kannel Lipids, diabetes, and coronary heart disease: insights from the Framingham Study Am Heart J 110 1985 1100 1107
11. S. Parish, A. Offer, R. Clarke, J.C. Hopewell, M.R. Hill, J.D. Otvos, J. Armitage, R. Collins Heart Protection Study Collaborative Group Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study Circulation 125 2012 2469 2478
12. A. Keech, R.J. Simes, P. Barter, J. Best, R. Scott, M.R. Taskinen, P. Forder, A. Pillai, T. Davis, P. Glasziou, P. Drury, Y.A. Kesäniemi, D. Sullivan, D. Hunt, P. Colman, M. d'Emden, M. Whiting, C. Ehnholm, M. Laakso FIELD Study Investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial Lancet 366 2005 1849 1861
13. AIM-HIGH Investigators W.E. Boden, J.L. Probstfield, T. Anderson, B.R. Chaitman, P. Desvignes-Nickens, K. Koprowicz, R. McBride, K. Teo, and W. Weintraub Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
14. H.J. Warraich, N.D. Wong, and J.S. Rana Role for combination therapy in diabetic dyslipidemia Curr Cardiol Rep 17 2015 32
15. Clinical Trials.Gov. Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh CV Risk PatienTs with Hypertriglyceridemia (STRENGTH). www.clinicaltrials.gov/ct2/show/NCT02104817?term=strength&;rank=7. Accessed July 1, 2015.
16. R.P. Giugliano, and M.S. Sabatine Are PCSK9 inhibitors the next breakthrough in the cardiovascular field? J Am Coll Cardiol 65 2015 2638 2651